GOTHENBURG, Sweden -- The investigational oral anticoagulant rivaroxaban (Xarelto), a selective factor Xa inhibitor, prevents venous thromboembolism after hip or knee arthroplasty better than enoxaparin (Lovenox), without a tradeoff in safety, according to two large international trials.
More...